Akari Therapeutics Past Earnings Performance
Past criteria checks 0/6
Akari Therapeutics has been growing earnings at an average annual rate of 2.9%, while the Biotechs industry saw earnings growing at 7.7% annually.
Key information
2.9%
Earnings growth rate
39.8%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | n/a |
| Return on equity | n/a |
| Net Margin | n/a |
| Last Earnings Update | 30 Sep 2024 |
Recent past performance updates
No updates
Recent updates
Revenue & Expenses Breakdown
How Akari Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Sep 24 | 0 | -20 | 9 | 8 |
| 30 Jun 24 | 0 | -20 | 10 | 8 |
| 31 Mar 24 | 0 | -17 | 12 | 6 |
| 31 Dec 23 | 0 | -10 | 11 | 5 |
| 30 Sep 23 | 0 | -10 | 12 | 7 |
| 30 Jun 23 | 0 | -10 | 13 | 8 |
| 31 Mar 23 | 0 | -12 | 13 | 9 |
| 31 Dec 22 | 0 | -18 | 14 | 10 |
| 30 Sep 22 | 0 | -20 | 12 | 11 |
| 30 Jun 22 | 0 | -18 | 10 | 8 |
| 31 Mar 22 | 0 | -17 | 9 | 8 |
| 31 Dec 21 | 0 | -17 | 8 | 9 |
| 30 Sep 21 | 0 | -18 | 8 | 10 |
| 30 Jun 21 | 0 | -16 | 8 | 9 |
| 31 Mar 21 | 0 | -19 | 8 | 10 |
| 31 Dec 20 | 0 | -17 | 9 | 9 |
| 30 Sep 20 | 0 | -18 | 8 | 10 |
| 30 Jun 20 | 0 | -21 | 8 | 13 |
| 31 Mar 20 | 0 | -18 | 8 | 14 |
| 31 Dec 19 | 0 | -17 | 8 | 9 |
| 30 Sep 19 | 0 | -13 | 8 | 5 |
| 30 Jun 19 | 0 | -14 | 9 | 7 |
| 31 Mar 19 | 0 | -18 | 10 | 8 |
| 31 Dec 18 | 0 | -20 | 11 | 12 |
| 30 Sep 18 | 0 | -25 | 12 | 17 |
| 30 Jun 18 | 0 | -32 | 12 | 20 |
| 31 Mar 18 | 0 | -24 | 13 | 18 |
| 31 Dec 17 | 0 | -35 | 12 | 23 |
| 30 Sep 17 | 0 | -32 | 11 | 23 |
| 30 Jun 17 | 0 | -22 | 11 | 20 |
| 31 Mar 17 | 0 | -28 | 10 | 22 |
| 31 Dec 16 | 0 | -18 | 10 | 17 |
| 30 Sep 16 | 0 | -3 | 9 | 13 |
| 30 Jun 16 | 0 | -52 | 9 | 10 |
| 31 Mar 16 | 0 | -47 | 7 | 6 |
| 31 Dec 15 | 0 | -45 | 6 | 6 |
| 30 Sep 15 | 0 | -53 | 2 | 5 |
| 30 Jun 15 | 0 | -4 | 0 | 4 |
| 31 Mar 15 | 0 | -3 | 0 | 3 |
| 31 Dec 14 | 0 | -2 | 0 | 2 |
Quality Earnings: CLA is currently unprofitable.
Growing Profit Margin: CLA is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CLA is unprofitable, but has reduced losses over the past 5 years at a rate of 2.9% per year.
Accelerating Growth: Unable to compare CLA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CLA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: CLA's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.